JOHNS HOPKINS MEDICINE
JOHNS HOPKINS HEALTHCARE

Blenrep

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form along with supporting clinical documentation to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process.** If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____kg

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical* ❑ *Home* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office*

Drug Information:

Strength/Measure _____ *Units* ❑ ml ❑ Gm ❑ mg ❑ ea ❑ Un
Directions(sig) _____ *Route of administration* _____
Dosing frequency _____

Send completed form to: Priority Partners Fax: 1-866-212-4756

 Blenrep SGM 4070-A – 04/2023.

Priority Partners ● 7231 Parkway Drive Suite 100 ● Hanover, MD 21076
Phone: 888-819-1043 ● Fax: 1-866-212-4756 ● www.jhhc.com

Clinical Criteria Questions:

What is the ICD-10 code? _____

1. What is the diagnosis?

❒ Multiple Myeloma, *Continue to #100*

❒ Other, *Continue to #100*

Multiple Myeloma

Continuation

100. Is the patient currently receiving treatment with the requested medication?

❒ Yes, *Continue to #101*

❒ No, *Continue to #150*

101. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?

❒ Yes, *No Further Questions*

❒ No, *No Further Questions*

Initial

150. What is the clinical setting in which the requested medication will be used?

❒ Relapsed disease, *Continue to #151*

❒ Refractory disease, *Continue to #151*

❒ Progressive disease, *Continue to #151*

❒ Other, *Continue to #151*

151. Has the patient received at least four prior therapies for multiple myeloma, including at least one drug from each of the following categories: A) anti-CD38 monoclonal antibody (e.g., daratumumab), B) proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib), and C) immunomodulatory agent (e.g., lenalidomide, pomalidomide)?

❒ Yes, *Continue to #152*

❒ No, *Continue to #152*

152. Will the requested drug be used as a single agent?

❒ Yes, *No Further Questions*

❒ No, *No Further Questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X_____

Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Priority Partners Fax: 1-866-212-4756

Priority Partners ● 7231 Parkway Drive Suite 100 ● Hanover, MD 21076

Phone: 888-819-1043 ● Fax: 1-866-212-4756 ● www.jhhc.com